Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Indianapolis, Indiana 46202


Purpose:

The purpose of this study is to determine the maximum tolerated dose of alloreactive NK cells that can be transfused following stem cell transplant.


Criteria:

Inclusion Criteria: - Patients must have histologically documented AML, ALL, MDS, CML, - Identification of haploidentical donor - LVEF > 45% corrected - DLCO > 50% predicted - Serum Creatinine <= 2 mg/dL - Bilirubin < 2 x ULN - AST, ALT < 2 x ULN - Age ≤ 65 years - Performance Status 0-1 Exclusion Criteria: - Patients relapsing <6 months after autologous SCT are not eligible. - Patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection - No HIV disease - Non-pregnant and non-nursing


NCT ID:

NCT00569179


Primary Contact:

Principal Investigator
Sherif Farag, MD, PhD
Indiana University School of Medicine


Backup Contact:

N/A


Location Contact:

Indianapolis, Indiana 46202
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 20, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.